A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Konstantin Doberer et al.|New England Journal of Medicine|2024Cited by 151
Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammationMatthias Diebold, Georg A. Böhmig, Hannes Vietzen et al.|American Journal of Transplantation|2023Cited by 26
Natural Killer Cell Presence in Antibody-Mediated RejectionMatthias Diebold, Georg A. Böhmig, Evan A. Farkash et al.|Transplant International|2024Cited by 19
Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant OutcomeHannes Vietzen, Georg A. Böhmig, Bernd Döhler et al.|Frontiers in Immunology|2022Cited by 18
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort StudyMatthias Diebold, Georg A. Böhmig, Hannes Vietzen et al.|Transplantation|2024Cited by 13